Patent intelligence · US
US 12233106
C-type natriuretic peptide variants to treat skeletal dysplasia in children
C-type natriuretic peptide variants to treat skeletal dysplasia in children
Patent details — US 12233106
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 25, 2025
- Expiration
- Feb 20, 2045
- Applicant
- BIOMARIN PHARMACEUTICAL INC.
- Claims
- 14
- CPC classes
- A61K, A61K38/1709, A61K38/2242, A61K47/10
Quick answer
US 12233106 (C-type natriuretic peptide variants to treat skeletal dysplasia in children) is held by BIOMARIN PHARMACEUTICAL INC.. Status: granted. Granted Feb 25, 2025. Expires Feb 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOMARIN PHARMACEUTICAL INC.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K38/1709, A61K38/2242, A61K47/10, A61K47/12, A61K47/183
More from BIOMARIN PHARMACEUTICAL INC.
Related pharmaceutical patents in our USPTO index.
-
US 12427171
Krill oil composition enriched in LPC-DHA and LPC-EPA
granted -
US 12331293
Bispecific antisense oligonucleotides for dystrophin exon skipping
granted -
US 12239692
Adeno-associated virus factor VIII vectors
granted -
US 12214015
Use of c-type natriuretic peptide variants to treat osteoarthritis
granted -
US 12194064
Process of producing concentrated therapeutic phospholipid composition from krill extracts containing high level of free fatty acids
granted -
US 12188058
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
granted -
US 12076372
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
granted
Frequently asked questions
What is US patent 12233106?
US 12233106 (C-type natriuretic peptide variants to treat skeletal dysplasia in children) is held by BIOMARIN PHARMACEUTICAL INC.. Status: granted. Granted Feb 25, 2025. Expires Feb 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12233106?
BIOMARIN PHARMACEUTICAL INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 175 pharmaceutical patents for this assignee.
When does US 12233106 expire?
Our index shows an expiration date of Feb 20, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.